secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001628280-23-000738
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion prelim Q4 2022 US revenue $14.4-15.1M (+38-40% YoY); CLEAR Outcomes submissions planned 1H 2023
--------------------------------------------------------------------------------

- Preliminary Q4 2022 U.S. net product revenue $14.4M-$15.1M; full-year 2022 growth 38%-40% YoY.
- Cash and investment securities ~$167M as of Dec 31, 2022; ~74.6M shares outstanding.
- Plans to submit CLEAR Outcomes data to FDA and EMA in 1H 2023; expects partner milestone payments upon approvals.
- Announces 12-month marketing partnership with RFK Racing to boost brand awareness among 10M+ fans.
- Presenting at J.P. Morgan 41st Annual Healthcare Conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/0001628280-23-000738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/espr-20230108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer